We are monitoring the impact of COVID-19 on MEA Multiple Myeloma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 804
Share on
Share on

Middle East & Africa Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 804
Pages: 134

MEA Multiple Myeloma Therapeutics Market Size & Growth (2021 to 2026)

Middle East and Africa Multiple Myeloma Therapeutics Market was worth USD 733.18 Million in 2021 and estimated to be growing at a CAGR of 4.74%, to reach USD 924.22 Million by 2026.

Multiple myelomas (MM) is a malignant plasma cell disorder that accounts for almost 10% of all hematologic cancers. Immunotherapy is the latest methodology for multiple myeloma treatment. It is an umbrella term that defines different ways to inspire the immune system and improve its capability to attack cancer cells. Chemicals are released by multiplying myeloma plasma cells that consequence in dissolving and damaging bones.

Factors such as varied therapeutic areas, rising investment in research and development for new therapies, increasing demand and extensive off-label use of IG are some of the foremost factors contributing to the growth of the multiple myeloma therapeutics market.

Stringent regulations and reimbursement issues are the key factors probable to obstruct the multiple myeloma therapeutics market growth.

This research report on the MEA Multiple Myeloma Therapeutics Market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, Africa dominates the multiple myeloma therapeutics market while Middle-East is anticipated to grow at the highest rate in the forecast period.

The leading companies leading in the MEA Multiple Myeloma Therapeutics Market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd.,TG Therapeutics Inc. and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Treatment Type                 

                                5.1.1 Chemotherapy      

                                       Anthracycline antibiotic

                                       Alkylating agent

                                5.1.2 Targeted Therapy

                                       Proteasome inhibitor

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                       Dexamethasone (Decadron)

                                       Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                       Thalidomide (Thalomid)

                                       Lenalidomide (Revlimid)

                                       Arsenic trioxide (Trisenox)

                                       Plerixafor (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 Middle-East                                

                6.3 Africa                            

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)                    

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 


                a) List of Tables                

                b) List of Figures                              

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

Request Sample to View List of Tables & Figures

Please wait. . . . Your request is being processed

Related Reports


$ 1234 2875

Click for Request Sample